Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

EvoLV Success Stories: Transformative Results in Life Sciences Consulting

Apr 05, 2026

Driving Innovation in Life Sciences

In the ever-evolving world of life sciences, consulting plays a pivotal role in guiding companies toward innovation and success. EvoLV, a leader in this field, has consistently delivered transformative results for its clients. By leveraging deep industry knowledge and cutting-edge strategies, EvoLV ensures that businesses not only keep pace with rapid developments but also lead the charge.

One of the key factors that sets EvoLV apart is its commitment to understanding the unique challenges faced by each client. This personalized approach allows the consulting team to devise solutions that are not only effective but also sustainable in the long term.

life sciences innovation

Strategic Approaches to Complex Challenges

Life sciences companies often encounter complex challenges that require innovative solutions. EvoLV specializes in crafting strategic approaches that address these challenges head-on. By conducting thorough market analyses and leveraging the latest technologies, EvoLV helps clients navigate regulatory landscapes, optimize processes, and enhance product development.

An example of this is a recent collaboration with a biotech firm struggling with lengthy product development cycles. EvoLV's intervention resulted in a 30% reduction in time-to-market, significantly boosting the company's competitive edge.

biotech collaboration

Empowering Growth Through Data-Driven Insights

Data is at the heart of decision-making in the life sciences industry. EvoLV's expertise in data analytics enables clients to harness the power of data effectively. By transforming raw data into actionable insights, EvoLV empowers companies to make informed decisions that drive growth and innovation.

For instance, a pharmaceutical company partnered with EvoLV to optimize its supply chain. Through advanced data analysis, EvoLV identified key areas for improvement, resulting in a 15% increase in operational efficiency.

data analysis life sciences

Fostering Sustainable Practices

Sustainability is becoming increasingly crucial in life sciences. EvoLV is at the forefront of promoting sustainable practices, helping clients reduce their environmental impact while maintaining profitability. By integrating sustainability into their core strategies, companies can achieve a balance between economic growth and ecological responsibility.

One success story involves a medical device manufacturer that, with EvoLV's guidance, implemented environmentally friendly production techniques, reducing waste by 40% and setting a new standard in the industry.

Building Collaborative Partnerships

Success in life sciences often hinges on collaboration. EvoLV excels in building strong partnerships with clients, fostering an environment of trust and shared goals. This collaborative approach ensures that solutions are aligned with the client's vision and objectives.

Through workshops, training sessions, and ongoing support, EvoLV empowers teams to embrace change and drive innovation from within, leading to sustainable success.

team collaboration life sciences

Conclusion: Paving the Way for Future Success

EvoLV's success stories in life sciences consulting highlight the transformative impact of strategic guidance and innovative solutions. By addressing complex challenges, leveraging data-driven insights, promoting sustainability, and fostering collaboration, EvoLV paves the way for future success in the industry.

As the life sciences sector continues to evolve, EvoLV remains a trusted partner for companies seeking to innovate and excel. With a proven track record of results, EvoLV is committed to shaping the future of life sciences with its visionary consulting approach.